Clinical Trial Update: A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trials update covers a Phase I/II study of the MUC1 inhibitor GO-203-2C in adults with relapsed or refractory acute myeloid leukemia. The trial st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• GO-203-2C (GO-203-2C)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED